Cargando…
Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks
Agomelatine (AGM) was approved for the treatment of major depressive disorder (MDD) in adults by the European Medicines Agency (EMA) in February 2009. It is an analogue of melatonin and features a unique pharmacodynamic profile with agonism on both types of melatonergic receptors (MT1/MT2) and antag...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bentham Science Publishers
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243030/ https://www.ncbi.nlm.nih.gov/pubmed/25426008 http://dx.doi.org/10.2174/1570159X12999140619122914 |